Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RORA | P35398 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067200 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2TSHRARMEN1ALOX15 | |
| SCHEMBL4609823 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2TSHRARMEN1ALOX15 | |
| SCHEMBL19179688 | 0.82 | ESR1 (0.46) | SMN1; SMN2TSHRESR1ARESR2 | |
| SCHEMBL7102669 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRARMEN1ALOX15 | |
| SCHEMBL309960 | 0.81 | NR1H2 (0.52) | SMN1; SMN2TSHRARMEN1ALOX15 | |
| SCHEMBL11371728 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2TSHRARMEN1ALOX15 | |
| SCHEMBL29509486 | 0.80 | MEN1 (0.47) | SMN1; SMN2TSHRARMEN1ALOX15 | |
| SCHEMBL17709790 | 0.80 | MEN1 (0.47) | SMN1; SMN2TSHRARMEN1ALOX15 | |
| SCHEMBL13974786 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2TSHRARMEN1ALOX15 | |
| SCHEMBL2754718 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRARMEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245633-A1 | ROR Gamma Agonists as Enhancers of Protective Immunity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-07-25 | — | — | US | disclosed |
| US-11084784-B2 | ROR-gamma modulators and uses thereof | Piramal Enterprises Limited (IN) | 2021-08-10 | — | — | US | disclosed |
| CN-110272361-A | The phthalic diamides compound of the hexafluoro isopropyl containing alkoxy and its application | 华东理工大学 | 2019-09-24 | — | — | CN | disclosed |
| EP-3077372-B1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2019-02-06 | — | — | EP | disclosed |
| US-20180215707-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2018-08-02 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| EP-3077372-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Cel Models IP B.V. (NL) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015082533-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2015-06-11 | — | — | WO | disclosed |
| US-20140187554-A1 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2012158784-A2 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | KAMENECKA THEODORE MARK (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245633-A1 | ROR Gamma Agonists as Enhancers of Protective Immunity | RORC, RORB, RORA | SMN1; SMN2 3772/4885TSHR 371/4885ESR1 1915/4885 |
| US-20140187554-A1 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | RORB, RORA, RORC | SMN1; SMN2 2502/4885TSHR 59/4885ESR1 505/4885 |
| US-11084784-B2 | ROR-gamma modulators and uses thereof | RORB, RORA, RORC | SMN1; SMN2 1625/4885TSHR 835/4885ESR1 879/4885 |
| US-20180215707-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | RORB, RORA, RORC | SMN1; SMN2 1625/4885TSHR 835/4885ESR1 879/4885 |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | RORC, RORA, RORB | SMN1; SMN2 3833/4885TSHR 167/4885ESR1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.